Organization
Sorbonne Université
17 abstracts
Abstract
Survival outcomes associated with first-line PCV or temozolomide in combination with radiotherapy in IDH-mutant 1p/19q-codeleted grade 3 oligodendroglioma.Org: Paris Brain Institute (ICM), Service de Neurologie 2 Mazarin, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, AP-HP, Sorbonne Université, Lyon HCL,
Abstract
Nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) as first-line (1L) treatment for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Expanded efficacy analysis from CheckMate 8HW.Org: Bristol Myers Squibb, Cancer Research SA, Fondazione Policlinico Universitario A. Gemelli IRCCS, Institut Paoli-Calmettes, Marseille, France, Instituto Catalán de Oncología,
Abstract
Transcriptomic signatures of MSI-high metastatic colorectal cancer to predict efficacy of immune checkpoint inhibitors.Org: Institut du Cancer Paris CARPEM, APHP-INSERM U1149 Universite Paris Diderot, Digestive Oncology Department, APHP.Centre - Université Paris Cité, Hôpital Européeen G. Pompidou,
Abstract
Longitudinal assessment of cardiac involvement in Erdheim-Chester disease using cardiac magnetic resonance imaging.Org: Hôpital Pitié-Salpêtrière, Service de Médecine Interne 2, Hôpital Pitié Salpêtrière, Assistance Publique Hôpitaux de Paris (AP-HP), Department of Internal Medicine C, University Hospital Greifswald, Greifswald, Germany,
Abstract
EO2401 (E) peptide immunotherapy + nivolumab (N) +/- bevacizumab (B) in recurrent glioblastoma (GB): EOGBM1-18/ROSALIE.Org: Universitätsklinikum Heidelberg, German Cancer Research Center, Sorbonne Université, AP-HP at Saint-Louis Hospital, ICM,
Abstract
HER2 testing in the MOUNTAINEER trial: Analysis of treatment response based on central HER2 assessment using IHC/ISH and NGS.Org: Duke University Medical Center, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute, Grande Ospedale Metropolitano Niguarda and Università degli Studi di Milano,
Abstract
Trastuzumab-deruxtecan in HER2-low metastatic/unresectable breast cancer: Real life data in two Parisian centers.Org: Hôpital Tenon, Institut Universitaire de Cancérologie, Sorbonne Université, APHP-INSERM U1149 Universite Paris Diderot, Hôpital La Pitié-Salpêtrière,
Abstract
Identifying anatomopathological factors associated with a Oncotype DX 21-gene recurrence score higher than 25 in menopaused women.Org: Assistance Publique des Hôpitaux de Paris, Hôpital Tenon, Institut Universitaire de Cancérologie, Sorbonne Université, APHP-INSERM U1149 Universite Paris Diderot,
Abstract
BRCA1 and RAD51 methylation impact on outcome in patients with advanced ovarian cancer: A PAOLA-1 ancillary study.Org: APHP-INSERM U1149 Universite Paris Diderot, European Georges Pompidou Hospital, Centre de Recherche des Cordeliers, Université de Paris, Sorbonne Université,
Abstract
Effect of dual properties of regorafenib in osteosarcoma on tumor progression and bone parameters in mouse preclinical models.Org: ICO Institut de Cancerologie de l'Ouest, Department of Basic Studies, Faculty of Odontology, University of Antioquia, Institut de Cancérologie de l'Ouest (ICO)-site René Gauducheau, Hephaistos Pharma, Léon Bérard Centre,
Abstract
APPLICATION OF MACHINE LEARNING METHODS TO PREDICT SF-36 MENTAL HEALTH DOMAIN FOR SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTSOrg: Sorbonne Université, Bioinformatics and Biostatistics Unit, Science and Engineering, Paris, France,
Abstract
ADALIMUMAB FOR IMMUNE RELATED INFERTILITY: EFFICACY AND SAFETY FROM PROSPECTIVE FRENCH MULTICENTER REGISTRYOrg: Sorbonne Université, AP-HP at Saint-Louis Hospital, Hôpital Saint Antoine, Assistance Publique Hôpitaux de Paris, Service de médecine interne et Inflammation-Immunopathology-Biotherapy Department (DMU i3), Paris, France,
Abstract
ANTI PM-SCL ASSOCIATED AUTO IMMUNE DISEASES: MULTICENTRIC COHORT OF 128 PATIENTSOrg: Assistance Publique-Hôpitaux de Paris, Hôpital Cochin, Centre de Référence pour les Maladies Auto-immunes Rares, Université de Paris, Médecine Interne, CHU Estaing, Clermont-Ferrand, France,
Abstract
BIMEKIZUMAB SAFETY AND EFFICACY IN PATIENTS WITH PSORIATIC ARTHRITIS: 3-YEAR RESULTS FROM A PHASE 2b OPEN-LABEL EXTENSION STUDYOrg: UCB Pharma, Brigham and Women’s Hospital, Sorbonne Université, University of Rochester Medical School, University of Oxford,
Abstract
BLISS-LN: A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 TRIAL OF INTRAVENOUS BELIMUMAB IN PATIENTS WITH ACTIVE LUPUS NEPHRITISOrg: Northwell Health, New Hyde Park, NY, Cliniques Universitaires Saint-Luc, Sorbonne Université, Escola de Medicina e Saúde Pública, Organizacion Medica de Investigacion,
Abstract
BIMEKIZUMAB IN BDMARD-NAIVE PATIENTS WITH PSORIATIC ARTHRITIS: 24-WEEK EFFICACY & SAFETY FROM BE OPTIMAL, A PHASE 3, MULTICENTRE, RANDOMISED, PLACEBO-CONTROLLED, ACTIVE REFERENCE STUDYOrg: UCB Pharma, Brigham and Women's Hospital/Massachusetts General Hospital, University of Glasgow, University of Oxford, Oxford University Hospitals NHS Trust,
Abstract
BARRIERS TO PHYSICAL ACTIVITY COLLECTED BY THE IFAB QUESTIONNAIRE CORRELATE WITH LEVELS OF PHYSICAL ACTIVITY IN PATIENTS WITH RHEUMATOID ARTHRITIS OR SPONDYLOARTHRITIS: A CROSS-SECTIONAL STUDY OF 150 PATIENTSOrg: Sorbonne Université, Inserm U567, Institut Pierre Louis d’Épidémiologie et de Santé Publique, PEPITES, Hôpital Charles Nicolle,